Share Price and Basic Stock Data
Last Updated: November 20, 2025, 9:51 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Centenial Surgical Suture Ltd operates within the medical equipment and accessories sector, focusing on surgical sutures. The company’s revenue trends for the past several quarters indicate a relatively stable performance. Quarterly sales stood at ₹11.75 Cr in March 2022 and peaked at ₹13.74 Cr in June 2024, before declining to ₹12.05 Cr in March 2025. The annual sales figures also reflect a similar pattern, with a recorded ₹52.66 Cr for the fiscal year ending March 2023, slightly decreasing to ₹51.19 Cr in March 2024, before rebounding to ₹53.49 Cr in March 2025. This fluctuation in sales may suggest that while the company has managed to recover from previous low points, consistent growth remains a challenge. Overall, the revenue trajectory indicates potential for growth, albeit with periodic dips that warrant further strategic analysis.
Profitability and Efficiency Metrics
Centenial Surgical Suture Ltd’s profitability metrics reveal a mixed performance, with a reported operating profit margin (OPM) of 15.48% in March 2025, showcasing an improvement from previous quarters. However, the company’s net profit has been under pressure, with a net profit of -₹2.08 Cr reported for the trailing twelve months (TTM) ending March 2025, a stark decline from ₹1.13 Cr in March 2024. The interest coverage ratio (ICR) stood at 1.70x, indicating that the company is barely covering its interest obligations, which could pose a risk during downturns. Additionally, the cash conversion cycle (CCC) of 895.19 days suggests inefficiencies in managing inventory and receivables, which could further strain profitability if not addressed. The combination of high operating margins against a backdrop of negative net profit underscores the need for operational improvements and strategic cost management.
Balance Sheet Strength and Financial Ratios
Centenial Surgical Suture Ltd’s balance sheet reflects a moderate financial structure, with total borrowings reported at ₹0 Cr, indicating the absence of debt, which is a notable strength. However, the company’s return on equity (ROE) stood at a low 4.64%, and return on capital employed (ROCE) was recorded at 3.94%, both indicating underperformance relative to industry benchmarks. The price-to-book value ratio (P/BV) of 1.94x suggests the market values the company at a premium compared to its book value, potentially reflecting investor confidence despite weak profitability metrics. The current ratio of 1.98x indicates a comfortable liquidity position, allowing the company to meet its short-term obligations. However, the inventory turnover ratio of 0.38x highlights potential inefficiencies in inventory management, which could impact cash flow and operational agility.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Centenial Surgical Suture Ltd shows a stable distribution, with promoters holding 46.89% of the shares, while the public holds 53.11%. The number of shareholders has increased from 911 in December 2022 to 1,193 by March 2025, reflecting a growing interest among retail investors. This trend may indicate increasing confidence in the company’s potential for recovery and growth. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises concerns about the broader institutional backing, which can be critical for stability and long-term growth. The promoter stake, while substantial, could also lead to governance risks if not balanced with public interests. Enhanced transparency and operational performance could be essential to attract institutional investments and bolster shareholder confidence.
Outlook, Risks, and Final Insight
Looking ahead, Centenial Surgical Suture Ltd faces both opportunities and challenges. The potential for revenue growth exists, especially given the recent increase in sales figures; however, the company must address profitability issues and operational inefficiencies to sustain this growth. Key risks include the ongoing negative net profit and high cash conversion cycle, which could hinder financial stability. If the company can streamline operations and improve its inventory management, it may enhance both its profitability and investor sentiment. Conversely, failure to rectify these issues could lead to further declines in shareholder confidence and financial performance. The company’s future will significantly depend on its ability to balance operational effectiveness with strategic growth initiatives, ensuring sustainable profitability in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Centenial Surgical Suture Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 79.5 Cr. | 63.4 | 140/46.0 | 18.1 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 37.0 Cr. | 101 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 26.0 Cr. | 18.0 | 26.5/15.0 | 12.6 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 19,034 Cr. | 1,879 | 3,095/1,821 | 52.6 | 288 | 0.19 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 75.8 Cr. | 41.6 | 86.9/41.2 | 22.7 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 19,034.00 Cr | 420.60 | 26.50 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.75 | 13.49 | 13.01 | 13.13 | 13.02 | 13.66 | 13.10 | 12.38 | 12.05 | 13.74 | 14.27 | 12.20 | 13.31 |
| Expenses | 10.61 | 12.38 | 11.98 | 12.06 | 11.92 | 12.50 | 11.96 | 11.19 | 10.54 | 12.02 | 12.54 | 11.45 | 11.25 |
| Operating Profit | 1.14 | 1.11 | 1.03 | 1.07 | 1.10 | 1.16 | 1.14 | 1.19 | 1.51 | 1.72 | 1.73 | 0.75 | 2.06 |
| OPM % | 9.70% | 8.23% | 7.92% | 8.15% | 8.45% | 8.49% | 8.70% | 9.61% | 12.53% | 12.52% | 12.12% | 6.15% | 15.48% |
| Other Income | 0.04 | 0.00 | 0.08 | 0.02 | 0.03 | 0.01 | 0.02 | 0.06 | 0.03 | 0.00 | 0.06 | 0.01 | 0.05 |
| Interest | 0.52 | 0.37 | 0.39 | 0.39 | 0.52 | 0.48 | 0.52 | 0.51 | 0.95 | 0.53 | 0.53 | 0.50 | 2.19 |
| Depreciation | 0.37 | 0.34 | 0.31 | 0.34 | 0.31 | 0.30 | 0.32 | 0.33 | 0.44 | 0.79 | 1.09 | 1.11 | 1.26 |
| Profit before tax | 0.29 | 0.40 | 0.41 | 0.36 | 0.30 | 0.39 | 0.32 | 0.41 | 0.15 | 0.40 | 0.17 | -0.85 | -1.34 |
| Tax % | 68.97% | 25.00% | 26.83% | 22.22% | 53.33% | 25.64% | 28.12% | 24.39% | -26.67% | 25.00% | 23.53% | 0.00% | -11.19% |
| Net Profit | 0.08 | 0.30 | 0.30 | 0.28 | 0.14 | 0.29 | 0.24 | 0.31 | 0.19 | 0.30 | 0.13 | -0.85 | -1.18 |
| EPS in Rs | 0.22 | 0.82 | 0.82 | 0.77 | 0.38 | 0.79 | 0.66 | 0.85 | 0.52 | 0.82 | 0.36 | -2.33 | -3.23 |
Last Updated: May 31, 2025, 6:34 am
Below is a detailed analysis of the quarterly data for Centenial Surgical Suture Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 13.31 Cr.. The value appears strong and on an upward trend. It has increased from 12.20 Cr. (Dec 2024) to 13.31 Cr., marking an increase of 1.11 Cr..
- For Expenses, as of Mar 2025, the value is 11.25 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.45 Cr. (Dec 2024) to 11.25 Cr., marking a decrease of 0.20 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.75 Cr. (Dec 2024) to 2.06 Cr., marking an increase of 1.31 Cr..
- For OPM %, as of Mar 2025, the value is 15.48%. The value appears strong and on an upward trend. It has increased from 6.15% (Dec 2024) to 15.48%, marking an increase of 9.33%.
- For Other Income, as of Mar 2025, the value is 0.05 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Dec 2024) to 0.05 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Mar 2025, the value is 2.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.50 Cr. (Dec 2024) to 2.19 Cr., marking an increase of 1.69 Cr..
- For Depreciation, as of Mar 2025, the value is 1.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.11 Cr. (Dec 2024) to 1.26 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Mar 2025, the value is -1.34 Cr.. The value appears to be declining and may need further review. It has decreased from -0.85 Cr. (Dec 2024) to -1.34 Cr., marking a decrease of 0.49 Cr..
- For Tax %, as of Mar 2025, the value is -11.19%. The value appears to be improving (decreasing) as expected. It has decreased from 0.00% (Dec 2024) to -11.19%, marking a decrease of 11.19%.
- For Net Profit, as of Mar 2025, the value is -1.18 Cr.. The value appears to be declining and may need further review. It has decreased from -0.85 Cr. (Dec 2024) to -1.18 Cr., marking a decrease of 0.33 Cr..
- For EPS in Rs, as of Mar 2025, the value is -3.23. The value appears to be declining and may need further review. It has decreased from -2.33 (Dec 2024) to -3.23, marking a decrease of 0.90.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.96 | 51.71 | 51.39 | 52.84 | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 53.49 | 51.91 |
| Expenses | 46.39 | 46.47 | 46.71 | 47.95 | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 47.07 | 46.48 |
| Operating Profit | 4.57 | 5.24 | 4.68 | 4.89 | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.40 | 5.15 | 6.42 | 5.43 |
| OPM % | 8.97% | 10.13% | 9.11% | 9.25% | 8.48% | 9.65% | 10.66% | 13.84% | 10.11% | 8.36% | 10.06% | 12.00% | 10.46% |
| Other Income | 0.04 | 0.10 | 0.02 | 0.01 | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.12 | 0.11 |
| Interest | 1.31 | 1.61 | 1.65 | 1.77 | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 3.90 | 3.47 |
| Depreciation | 0.59 | 0.83 | 0.68 | 0.59 | 0.60 | 0.69 | 1.55 | 1.55 | 1.53 | 1.30 | 1.39 | 4.25 | 4.31 |
| Profit before tax | 2.71 | 2.90 | 2.37 | 2.54 | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | -1.61 | -2.24 |
| Tax % | 33.95% | 34.14% | 34.18% | 32.68% | 36.10% | 29.12% | 39.81% | 37.25% | 42.06% | 39.73% | 11.02% | -9.32% | |
| Net Profit | 1.79 | 1.92 | 1.56 | 1.72 | 1.54 | 2.02 | 1.30 | 0.96 | 0.63 | 0.89 | 1.13 | -1.46 | -2.08 |
| EPS in Rs | 4.91 | 5.26 | 4.28 | 4.71 | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.10 | -4.00 | -5.70 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 7.26% | -18.75% | 10.26% | -10.47% | 31.17% | -35.64% | -26.15% | -34.38% | 41.27% | 26.97% | -229.20% |
| Change in YoY Net Profit Growth (%) | 0.00% | -26.01% | 29.01% | -20.72% | 41.63% | -66.81% | 9.49% | -8.22% | 75.64% | -14.30% | -256.17% |
Centenial Surgical Suture Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 6% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -287% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 29% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | -5% |
Last Updated: September 5, 2025, 2:51 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135.08 | 138.21 | 132.75 | 130.76 | 125.29 | 134.80 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 | 125.56 |
| Inventory Days | 297.67 | 350.07 | 365.93 | 468.59 | 465.89 | 434.68 | 483.86 | 1,276.44 | 599.23 | 677.26 | 909.72 | 921.61 |
| Days Payable | 162.36 | 167.34 | 124.26 | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159.00 | 222.42 | 207.75 | 151.98 |
| Cash Conversion Cycle | 270.39 | 320.94 | 374.42 | 453.06 | 455.54 | 449.22 | 449.14 | 1,125.08 | 600.67 | 597.56 | 836.02 | 895.19 |
| Working Capital Days | 122.62 | 127.27 | 148.80 | 156.25 | 164.05 | 167.69 | 172.36 | 282.37 | 236.68 | 207.73 | 226.67 | 210.99 |
| ROCE % | 13.25% | 14.08% | 11.59% | 11.40% | 9.78% | 11.62% | 10.84% | 8.65% | 7.27% | 8.03% | 8.07% | 3.94% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Diluted EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Cash EPS (Rs.) | 5.14 | 4.65 | 4.03 | 3.97 | 4.63 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Revenue From Operations / Share (Rs.) | 98.66 | 94.37 | 97.07 | 81.90 | 68.09 |
| PBDIT / Share (Rs.) | 11.77 | 9.46 | 8.16 | 8.28 | 9.40 |
| PBIT / Share (Rs.) | 3.92 | 6.90 | 5.76 | 5.47 | 6.54 |
| PBT / Share (Rs.) | -2.98 | 2.35 | 2.70 | 1.98 | 2.82 |
| Net Profit / Share (Rs.) | -2.70 | 2.09 | 1.63 | 1.16 | 1.77 |
| PBDIT Margin (%) | 11.92 | 10.02 | 8.40 | 10.11 | 13.80 |
| PBIT Margin (%) | 3.97 | 7.30 | 5.93 | 6.67 | 9.60 |
| PBT Margin (%) | -3.02 | 2.48 | 2.77 | 2.41 | 4.14 |
| Net Profit Margin (%) | -2.73 | 2.21 | 1.68 | 1.41 | 2.60 |
| Return on Networth / Equity (%) | -4.75 | 3.52 | 2.85 | 2.07 | 3.25 |
| Return on Capital Employeed (%) | 4.03 | 8.08 | 8.37 | 8.00 | 9.20 |
| Return On Assets (%) | -1.73 | 1.43 | 1.33 | 1.02 | 1.37 |
| Total Debt / Equity (X) | 0.39 | 0.44 | 0.31 | 0.30 | 0.41 |
| Asset Turnover Ratio (%) | 0.65 | 0.70 | 0.82 | 0.67 | 0.53 |
| Current Ratio (X) | 1.98 | 1.99 | 2.04 | 2.20 | 1.92 |
| Quick Ratio (X) | 0.61 | 0.69 | 0.76 | 0.86 | 0.77 |
| Inventory Turnover Ratio (X) | 0.38 | 0.50 | 0.58 | 0.45 | 0.46 |
| Interest Coverage Ratio (X) | 1.70 | 2.08 | 2.66 | 2.37 | 2.53 |
| Interest Coverage Ratio (Post Tax) (X) | 0.60 | 1.46 | 1.53 | 1.33 | 1.48 |
| Enterprise Value (Cr.) | 71.71 | 63.31 | 43.04 | 41.99 | 34.92 |
| EV / Net Operating Revenue (X) | 1.34 | 1.24 | 0.81 | 0.94 | 0.94 |
| EV / EBITDA (X) | 11.23 | 12.34 | 9.72 | 9.35 | 6.85 |
| MarketCap / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| Price / BV (X) | 1.94 | 1.54 | 1.08 | 1.09 | 0.78 |
| Price / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| EarningsYield | -0.02 | 0.02 | 0.02 | 0.01 | 0.04 |
After reviewing the key financial ratios for Centenial Surgical Suture Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.14. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 5.14, marking an increase of 0.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 98.66. It has increased from 94.37 (Mar 24) to 98.66, marking an increase of 4.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.77. This value is within the healthy range. It has increased from 9.46 (Mar 24) to 11.77, marking an increase of 2.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.92. This value is within the healthy range. It has decreased from 6.90 (Mar 24) to 3.92, marking a decrease of 2.98.
- For PBT / Share (Rs.), as of Mar 25, the value is -2.98. This value is below the healthy minimum of 0. It has decreased from 2.35 (Mar 24) to -2.98, marking a decrease of 5.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 2. It has decreased from 2.09 (Mar 24) to -2.70, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 10.02 (Mar 24) to 11.92, marking an increase of 1.90.
- For PBIT Margin (%), as of Mar 25, the value is 3.97. This value is below the healthy minimum of 10. It has decreased from 7.30 (Mar 24) to 3.97, marking a decrease of 3.33.
- For PBT Margin (%), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 10. It has decreased from 2.48 (Mar 24) to -3.02, marking a decrease of 5.50.
- For Net Profit Margin (%), as of Mar 25, the value is -2.73. This value is below the healthy minimum of 5. It has decreased from 2.21 (Mar 24) to -2.73, marking a decrease of 4.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is -4.75. This value is below the healthy minimum of 15. It has decreased from 3.52 (Mar 24) to -4.75, marking a decrease of 8.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 8.08 (Mar 24) to 4.03, marking a decrease of 4.05.
- For Return On Assets (%), as of Mar 25, the value is -1.73. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to -1.73, marking a decrease of 3.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.39, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.70 (Mar 24) to 0.65, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.98, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.69 (Mar 24) to 0.61, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 4. It has decreased from 0.50 (Mar 24) to 0.38, marking a decrease of 0.12.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.70. This value is below the healthy minimum of 3. It has decreased from 2.08 (Mar 24) to 1.70, marking a decrease of 0.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 3. It has decreased from 1.46 (Mar 24) to 0.60, marking a decrease of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 71.71. It has increased from 63.31 (Mar 24) to 71.71, marking an increase of 8.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.34, marking an increase of 0.10.
- For EV / EBITDA (X), as of Mar 25, the value is 11.23. This value is within the healthy range. It has decreased from 12.34 (Mar 24) to 11.23, marking a decrease of 1.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For Price / BV (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.54 (Mar 24) to 1.94, marking an increase of 0.40.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.02, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Centenial Surgical Suture Ltd:
- Net Profit Margin: -2.73%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.03% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -4.75% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.61
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 26.5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.39
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.73%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | F-29, MIDC, Murbad Thane Maharashtra 421401 | admin@centenialindia.com http://www.centenialindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Majrekar | Managing Director & CEO |
| Ms. Anuradha Kashikar | Executive Director & CFO |
| Mr. Devraj T Poojary | Executive Director |
| Mr. Neel M Vora | Ind. Non-Executive Director |
| Mr. Ridhima B Limaye | Ind. Non-Executive Director |
| Mr. Akash S Modi | Ind. Non-Executive Director |
| Mr. Anuj V Shah | Ind. Non-Executive Director |